What is the current market size?

The Lung Cancer Surgery market size was valued at USD 1.2 billion in 2023, driven by rising cancer prevalence and advanced surgical adoption.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by aging populations and increased early diagnosis rates.

What drives market expansion?

Key drivers include rising smoking-related cases, innovations in minimally invasive surgery, and growing healthcare expenditure in developed regions.

What challenges persist?

High procedure costs, limited access in emerging economies, and risks of surgical complications hinder broader market penetration.

Which regions lead the market?

North America dominates due to advanced healthcare infrastructure, followed by Europe, with Asia-Pacific showing fastest growth potential.

Who are the top companies?

Leading firms include Medtronic, Johnson & Johnson, and Boston Scientific, offering robotic systems and specialized surgical instruments.

What future opportunities exist?

Opportunities lie in AI-enabled diagnostics, personalized treatment plans, and expanding access to underserved regions through telemedicine.

How does technology impact the market?

Robotic-assisted surgery and 3D imaging enhance precision, reducing recovery times and improving outcomes, thus boosting market demand.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA prioritize safety, requiring rigorous approvals for new devices, which may delay market entry but ensure quality.

Lung Cancer Surgery Growth Trends & Opportunity Analysis 2033

Lung Cancer Surgery by Application (Lobectomy, Removal Of Sleeve, Regional Excision, Lung Removed All, Minimally Invasive Surgery), by Types (Surgical Instruments, Monitoring And Visualization System), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Lung Cancer Surgery Market Size | CAGR 8.2 Forecast 2033

Lung Cancer Surgery Growth Trends & Opportunity Analysis 2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Lung Cancer Surgery Market Overview

The Lung Cancer Surgery market encompasses procedures such as lobectomy, wedge resection, and segmentectomy, primarily aimed at treating non-small cell and small cell lung cancer. As a critical segment of oncology care, this market is gaining relevance due to rising incidence rates and advancements in minimally invasive surgical techniques. The global Lung Cancer Surgery market size is projected to exceed USD 1.8 billion by 2033, driven by industry expansion in emerging economies and a growth outlook fueled by early detection initiatives and technological innovation.

Loading chart…

The market forecast indicates a compound annual growth rate (CAGR) of 6.2% from 2026 to 2033, with North America dominating the industry due to advanced healthcare infrastructure and high adoption of robotic surgery systems. Asia-Pacific, however, is the fastest-growing region, spurred by expanding access to diagnostics and rising awareness. Key forces shaping the industry include technology shifts toward AI-integrated surgical tools, regulatory approvals for novel therapies, and evolving patient preferences for outpatient procedures. While challenges like high treatment costs persist, strategic collaborations between medtech firms and healthcare providers are expected to unlock new growth opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	4.32 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Accuray; Angiodynamics; Ethicon; Intuitive Surgical [Intuitive Surgical]; Olympus [Olympus]; Teleflex; Ackermann Instrumente; Karl Storz; Scanlan International; Trokamed
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Technological advancements in robotic-assisted and minimally invasive surgical techniques are accelerating adoption in the Lung Cancer Surgery market, enhancing procedural precision and reducing recovery times, which drives demand among patients and healthcare providers.

Aging global populations and rising incidence of lung cancer due to tobacco use, pollution, and genetic factors are expanding the Lung Cancer Surgery market size, with emerging economies witnessing sharper growth due to improved early diagnosis rates.

Restraints2 items

High costs of advanced surgical systems and associated training limit accessibility, particularly in Lung Cancer Surgery market segments with price-sensitive populations, suppressing volume growth in low- and middle-income regions.

Stringent regulatory approvals for innovative devices and prolonged clinical trial timelines delay market entry, creating bottlenecks for players aiming to capitalize on the Lung Cancer Surgery market growth forecast.

Opportunities2 items

Expansion into untapped markets in Asia-Pacific and Latin America offers significant upside, driven by rising healthcare investments and collaborations between local hospitals and global surgical technology firms.

Personalized medicine approaches, including biomarker-driven surgical planning and AI-integrated diagnostics, present niche growth avenues for players seeking to differentiate in the Lung Cancer Surgery market.

Challenges2 items

Shortage of specialized thoracic surgeons and uneven distribution of expertise across regions hinder the scalability of complex procedures, creating operational risks for Lung Cancer Surgery market stakeholders.

Supply chain vulnerabilities for critical surgical devices, exacerbated by geopolitical tensions and component material shortages, threaten cost stability and product availability in the Lung Cancer Surgery market.

Market Segmentation

Loading chart…

The Lung Cancer Surgery market is segmented by Application into Early-Stage Treatment and Advanced-Stage Palliation. Early-Stage Treatment (70% of market volume) dominates due to curative interventions for localized tumors, driven by diagnostic advancements and surgical innovations like video-assisted thoracoscopic surgery (VATS). Advanced-Stage Palliation (30%) addresses symptom management in metastatic cases, relying on less invasive procedures to improve quality of life. This Lung Cancer Surgery segmentation reflects clinical priorities, with curative surgeries shaping market growth through procedural demand and technological integration, while palliative needs stabilize the sector through consistent, albeit smaller-scale, adoption.

The Types segment categorizes procedures into Lobectomy (65% market share) and Wedge Resection (35%). Lobectomy, the gold standard for non-small cell lung cancer, involves complete lobe removal, ensuring oncologic efficacy but requiring higher surgical precision. Wedge Resection, preferred for small tumors or patients with comorbidities, preserves lung tissue but carries higher recurrence risks. This market taxonomy underscores the tension between therapeutic outcomes and patient suitability, with Lobectomy dominating due to its role in curative care, while Wedge Resection gains traction in early-stage disease and suboptimal candidates, reflecting evolving clinical guidelines and personalized treatment paradigms.

Lung Cancer Surgery Segmentation Breakdown9 items

Application

Lobectomy

Removal Of Sleeve

Regional Excision

Lung Removed All

Minimally Invasive Surgery

Types

Surgical Instruments

Monitoring And Visualization System

Regional Insights

Loading chart…

The Lung Cancer Surgery market is dominated by North America, representing approximately 40% of global demand. This leadership stems from advanced healthcare infrastructure, high adoption of minimally invasive robotic procedures, and robust R&D investments. Europe follows as the second-largest region, driven by aging demographics, stringent regulatory frameworks ensuring quality care, and strong public-private partnerships. The fastest-growing region is Asia Pacific, fueled by rising lung cancer incidence, expanding middle-class access to premium healthcare, and government initiatives to modernize treatment ecosystems.

Key Regional Drivers5 items

North America: Policies favoring reimbursement for advanced surgeries, demographics with high prevalence of smoking-related cases, and infrastructure enabling high-tech adoption.

Europe: Demographics (aging populations), policies promoting early detection, and ecosystem maturity in thoracic surgical hubs.

Asia Pacific: Investments in oncology care, demographics with rising urbanization, and adoption of cost-effective surgical technologies.

Latin America: Growing infrastructure upgrades and partnerships with global MNCs to scale affordable treatments.

Middle East & Africa: Investments in healthcare modernization and rising awareness of early-stage intervention benefits.

The regional forecast highlights Asia Pacific’s potential to bridge the demand-supply gap, while North America and Europe remain pivotal in shaping innovation. Lung Cancer Surgery market growth will hinge on policy alignment, equitable infrastructure expansion, and cross-regional knowledge sharing to address disparities.

Competitive Landscape

The Lung Cancer Surgery competitive landscape remains moderately consolidated, with global players and regional specialists coexisting. Market dynamics are influenced by product innovation (e.g., robotic-assisted systems), regulatory approvals, and strategic partnerships to expand distribution. Key players leverage advanced certifications (e.g., FDA, CE) to differentiate offerings, while pricing strategies vary across geographies, balancing premium technology with cost-sensitive markets. The presence of both established medtech firms and niche innovators underscores a fragmented yet structured market, where differentiation hinges on clinical outcomes and procedural efficiency.

Competitive strategies emphasize R&D investment for next-generation devices, geographic expansion via joint ventures, and vertical integration to control supply chains. Differentiation spans technology (e.g., minimally invasive platforms), service models (e.g., training programs for surgeons), and localized manufacturing to reduce costs. A key challenge is margin pressure from payor reimbursement constraints, compounded by rising compliance costs under evolving regulatory frameworks. Companies are also addressing supply chain risks through dual-sourcing agreements and regional inventory hubs.

Intuitive Surgical: Innovation pipeline with da Vinci robotic platforms

Olympus: Product launches in flexible bronchoscopy systems

Ethicon: Strategic partnerships for thoracic stapler distribution

Accuray: Regional expansion in Asia-Pacific markets

Teleflex: OEM tie-ups for endoscopic device components

Karl Storz: Localization of manufacturing for cost optimization

Key Lung Cancer Surgery Companies10 items

Accuray

Angiodynamics

Ethicon

Intuitive Surgical [Intuitive Surgical]

Olympus [Olympus]

Teleflex

Ackermann Instrumente

Karl Storz

Scanlan International

Trokamed

Market Ecosystem

The Lung Cancer Surgery ecosystem spans upstream technology and material development, midstream device and system integration, and downstream clinical delivery. Value is created through innovations in surgical devices and therapies, streamlined by suppliers, manufacturers, and healthcare providers. Regulatory frameworks and clinical adoption rates determine how value is captured across the value chain analysis.

Raw material/component suppliers — provide biocompatible polymers, metals, and electronic components for surgical devices

OEMs — design and manufacture robotic systems, thoracoscopy tools, and implantable devices

Technology providers — develop imaging software, AI-driven diagnostics, and minimally invasive surgical platforms

Distributors — manage logistics and supply chains for device delivery to hospitals and surgical centers

Service providers — offer training, maintenance, and post-market support for advanced surgical technologies

End users — hospitals and specialty clinics performing lobectomies, segmentectomies, and other lung cancer procedures

Regulators — approve device safety, efficacy, and compliance with evolving clinical and manufacturing standards

Control points reside with regulators, who gatekeep product approvals, and OEMs, who drive technological differentiation. Dependency risks include raw material shortages and regulatory delays. End users face high switching costs due to specialized training and interoperability requirements with existing infrastructure. Regional variations emerge in healthcare reimbursement models and adoption rates for robotic-assisted techniques.

Recent Industry Insights

The Lung Cancer Surgery industry trends over the past 18 months reflect a surge in innovation and strategic collaboration. Partnerships between surgical technology firms and AI-driven diagnostic platforms have accelerated precision in preoperative planning, with companies like Johnson & Johnson and Medtronic integrating AI into robotic-assisted systems. Mergers & acquisitions have intensified, exemplified by Boston Scientific’s acquisition of a minimally invasive surgery startup to expand its thoracic portfolio. Product launches highlight advancements in robotic systems, such as Intuitive Surgical’s next-gen da Vinci platform, optimized for smaller surgical teams. Regulatory shifts emphasize digital health integration, with the FDA fast-tracking approvals for AI-powered intraoperative imaging tools. Enterprises are prioritizing cost-effective, minimally invasive procedures, aligning with patient demand for shorter recovery times. Funding rounds have surged, particularly for startups leveraging nanotechnology in surgical oncology, with Series B rounds exceeding $100M in 2024. Collectively, these trends underscore the industry’s pivot toward tech-enabled, patient-centric care models.

Analyst Overview

The Lung Cancer Surgery market outlook remains robust, driven by rising incidence rates, aging populations, and advancements in minimally invasive techniques. Market attractiveness is bolstered by unmet needs in early-stage diagnostics and post-operative care, creating opportunities for innovation. However, competitive intensity is high, with established players dominating while emerging firms target niche segments like robotic-assisted platforms. Strategic partnerships and mergers are critical differentiators in this space.

Key Insights4 items

Long-term outlook is optimistic, fueled by R&D in personalized medicine and improved survival rates.

Innovation landscape emphasizes AI-driven diagnostics and robotic surgical systems to enhance precision.

Demand–supply balance tilts toward deficit in emerging markets due to surgeon shortages and infrastructure gaps.

Key risk factors include regulatory delays, reimbursement constraints, and adverse event reporting impacting adoption.

11 items

1. Executive Summary

2. Lung Cancer Surgery Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Lung Cancer Surgery Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Lung Cancer Surgery Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Lobectomy

6.1.2. Removal Of Sleeve

6.1.3. Regional Excision

6.1.4. Lung Removed All

6.1.5. Minimally Invasive Surgery

6.2. Global Lung Cancer Surgery Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Surgical Instruments

6.2.2. Monitoring And Visualization System

6.3. Global Lung Cancer Surgery Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Lung Cancer Surgery Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Lung Cancer Surgery Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Lung Cancer Surgery Market Competition by Key Manufacturers

8.1. Global Lung Cancer Surgery Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Lung Cancer Surgery: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Accuray

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Angiodynamics

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Ethicon

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Intuitive Surgical [Intuitive Surgical]

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Olympus [Olympus]

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Teleflex

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Ackermann Instrumente

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Karl Storz

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Scanlan International

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Trokamed

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Lung Cancer Surgery Market

Figure 4: Global Lung Cancer Surgery Market: Drivers

Figure 5: Global Lung Cancer Surgery Market: Challenges

Figure 6: Global Lung Cancer Surgery Market: Trends

Figure 7: Global Lung Cancer Surgery Market: Opportunity

Figure 8: Global Lung Cancer Surgery Market: Restraint

Figure 9: Global Lung Cancer Surgery Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Lung Cancer Surgery Market Value (USD Million) By Region

Figure 15: Global Lung Cancer Surgery Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Lung Cancer Surgery Market Value (USD Million) By Region

Figure 23: Global Lung Cancer Surgery Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Lung Cancer Surgery Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Lung Cancer Surgery Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Lung Cancer Surgery Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Lung Cancer Surgery Market Value (USD Million) By Region

Table 10: Global Lung Cancer Surgery Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Lung Cancer Surgery Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Lung Cancer Surgery Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Lung Cancer Surgery Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Accuray Basic Information And Sales Area

Table 31: Accuray. Products Portfolio

Table 32: Angiodynamics Basic Information And Sales Area

Table 33: Angiodynamics. Products Portfolio

Table 34: Ethicon Basic Information And Sales Area

Table 35: Ethicon. Products Portfolio

Table 36: Intuitive Surgical [Intuitive Surgical] Basic Information And Sales Area

Table 37: Intuitive Surgical [Intuitive Surgical]. Products Portfolio

Table 38: Olympus [Olympus] Basic Information And Sales Area

Table 39: Olympus [Olympus]. Products Portfolio

Table 40: Teleflex Basic Information And Sales Area

Table 41: Teleflex. Products Portfolio

Table 42: Ackermann Instrumente Basic Information And Sales Area

Table 43: Ackermann Instrumente. Products Portfolio

Table 44: Karl Storz Basic Information And Sales Area

Table 45: Karl Storz. Products Portfolio

Table 46: Scanlan International Basic Information And Sales Area

Table 47: Scanlan International. Products Portfolio

Table 48: Trokamed Basic Information And Sales Area

Table 49: Trokamed. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Lung Cancer Surgery Market Value (USD Million) By Region

Table 55: Global Lung Cancer Surgery Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Lung Cancer Surgery Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	4.32 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Accuray; Angiodynamics; Ethicon; Intuitive Surgical [Intuitive Surgical]; Olympus [Olympus]; Teleflex; Ackermann Instrumente; Karl Storz; Scanlan International; Trokamed
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options